Avantor (NYSE:AVTR) and Accelerate Diagnostics (NASDAQ:AXDX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.
This is a breakdown of recent recommendations and price targets for Avantor and Accelerate Diagnostics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Avantor presently has a consensus price target of $20.81, indicating a potential upside of 9.25%. Accelerate Diagnostics has a consensus price target of $19.00, indicating a potential downside of 6.17%. Given Avantor’s stronger consensus rating and higher probable upside, equities analysts clearly believe Avantor is more favorable than Accelerate Diagnostics.
Earnings and Valuation
This table compares Avantor and Accelerate Diagnostics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Accelerate Diagnostics||$5.67 million||194.50||-$88.33 million||($1.62)||-12.50|
Avantor has higher earnings, but lower revenue than Accelerate Diagnostics.
This table compares Avantor and Accelerate Diagnostics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
50.6% of Accelerate Diagnostics shares are held by institutional investors. 47.6% of Accelerate Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Avantor beats Accelerate Diagnostics on 6 of the 9 factors compared between the two stocks.
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.